FDA Expands Dysport Use for Cerebral Palsy-Related Spasticity FDA Expands Dysport Use for Cerebral Palsy-Related Spasticity

Dysport (abobotulinumtoxinA) has been approved for expanded use to treat upper- and lower-limb spasticity, including that caused by cerebral palsy, for patients 2 and older.FDA Approvals
Source: Medscape Neurology and Neurosurgery Headlines - Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news